Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2026 07:22 ET | Source: Research and Markets

$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools and Reagents: Global Markets" has been added to ResearchAndMarkets.com's offering.The global market for cell and gene...
February 18, 2026 11:26 ET | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Report December 2025: Trump Administration Sets Deadline for Pharma Companies to Fulfill MFN Commitments/UK-US Tariff Deal and Pricing Reforms Position UK As Global Hub

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, December 2025" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...
February 18, 2026 11:04 ET | Source: Research and Markets

CAR T - Cell Therapy Competitive Landscape Research Report 2026: Comprehensive Insights About 250+ Companies and 500+ Drugs - Key Opportunities Lie in Targeting Hematologic Malignancies

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "CAR T - Cell Therapy - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. This report offers a comprehensive...
February 13, 2026 16:30 ET | Source: Longeveron

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron (LGVN) has appointed Stephen H. Willard as Chief Executive Officer.
February 12, 2026 07:30 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell...
February 05, 2026 17:15 ET | Source: Iovance Biotherapeutics, Inc.

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...
February 05, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
February 05, 2026 07:07 ET | Source: Pluristyx, Inc.

Pluristyx and Solesis Launch First-of-its-Kind PluriForm™-GFP-3D Transfection Kit, Solving Critical Bottlenecks in Suspension Culture Transfection

Pluristyx and Solesis launch ready-to-use kit combining high-quality pluripotent cells and mRNA technology with proprietary transfection technology
January 29, 2026 10:23 ET | Source: Research and Markets

Cell Therapy Collaboration and Licensing Agreements Trends Report 2025 with Directory of 989 Deals - Upfront, Milestone, Royalties, Company A-Z, Deal Type and Therapy Area

Dublin, Jan. 29, 2026 (GLOBE NEWSWIRE) -- The "Cell Therapy Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering. This report contains a...
January 28, 2026 10:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on...